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iTATE-OF-THE-ART PAPER1527Combining Loop Diuretics With Thiazide-Type Diuretics for Heart Failureacob C. Jentzer, Tracy A. DeWald, Adrian F. Hernandez
challenging subset of heart failure patients have fluid overload despite large doses of loop
iuretics. One approach is to add a thiazide-type diuretic to produce diuretic synergy via
sequential nephron blockade,” first described more than 40 years ago. Jentzer and colleagues
ummarize the existing literature evaluating the combination of loop and thiazide diuretics and
nd that it has never been subjected to large-scale clinical trials, but it can more than double daily
rine sodium excretion. The risks of combination therapy include severe hypokalemia, in addition
o hyponatremia, hypotension, and worsening renal function. Considerations about the prudent
se of this powerful therapy and a review of potential misconceptions are also provided.TATE-OF-THE-ART PAPER1535Biomarkers for the Diagnosis of Acute Aortic Dissectionaron M. Ranasinghe, Robert S. Bonser
cute aortic syndromes have high mortality without definitive, early treatment. Currently, a high
ndex of clinical suspicion is necessary to divert a patient into a definitive algorithm of imaging
tudies. A biomarker with high sensitivity would be helpful in guiding more patients to the
maging pathway, but specificity is needed to avoid unnecessary delays in treatments for other
onditions. C-reactive protein, D-dimers, soluble elastin fragments, and smooth muscle myosin
eavy chain are all potentially useful, and the data regarding their utility are described in this paper
y Ranasinghe and Bonser.CLINICAL RESEARCH NTERVENTIONAL CARDIOLOGY1542Meta-Analysis Shows New P2Y Inhibitors Reduce Mortality Compared With Clopidogrel12
nne Bellemain-Appaix, David Brieger, Farzin Beygui, Johanne Silvain, Ana Pena, Guillaume Cayla,
livier Barthélémy, Jean-Philippe Collet, Gilles Montalescot
ellemain-Appaix and colleagues performed a meta-analysis to determine if the new P2Y12
nhibitors improve clinical outcomes. Data from almost 50,000 subjects were included, with 94%
aving an acute coronary syndrome and 84% undergoing percutaneous coronary intervention
PCI). New P2Y12 inhibitors significantly reduced death (odds ratio: 0.83). In subjects who
nderwent PCI, new P2Y12 inhibitors also significantly reduced major adverse cardiac events and
tent thrombosis. While there was an increase in Thrombolysis In Myocardial Infarction major
leeding for “any” PCI, no difference was observed in PCI for ST-segment elevation myocardial
nfarction (STEMI). After PCI, new P2Y12 inhibitors reduce mortality compared with
clopidogrel, with a particularly favorable risk/benefit ratio in patients presenting with STEMI.(continued on page A-26)
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EARDIAC GENETICS1552No Association Between Polymorphism in KIF6 and CAD in 19 Case-Control Studieshemistocles L. Assimes, Hilma Ho´lm, Sekar Kathiresan, Muredach P. Reilly, Gudmar Thorleifsson,
enjamin F. Voight, Jeanette Erdmann, Christina Willenborg, Dhananjay Vaidya, Changchun Xie,
hris C. Patterson, Thomas M. Morgan, Mary Susan Burnett, Mingyao Li, Mark A. Hlatky,
oshua W. Knowles, John R. Thompson, Devin Absher, Carlos Iribarren, Alan Go, Stephen P. Fortmann,
tephen Sidney, Neil Risch, Hua Tang, Richard M. Myers, Klaus Berger, Monika Stoll, Svati H. Shah,
udmundur Thorgeirsson, Karl Andersen, Aki S. Havulinna, J. Enrique Herrera, Nauder Faraday,
oonhee Kim, Brian G. Kral, Rasika Mathias, Ingo Ruczinski, Bhoom Suktitipat, Alexander F. Wilson,
isa R. Yanek, Lewis C. Becker, Patrick Linsel-Nitschke, Wolfgang Lieb, Inke R. König,
hristian Hengstenberg, Marcus Fischer, Klaus Stark, Wibke Reinhard, Janina Winogradow, Martina Grassl,
nika Grosshennig, Michael Preuss, Stefan Schreiber, H-Erich Wichmann, Christa Meisinger, Jean Yee,
echiel Friedlander, Ron Do, James B. Meigs, Gordon Williams, David M. Nathan, Calum A. MacRae,
iming Qu, Robert L. Wilensky, William H. Matthai Jr, Atif N. Qasim, Hakon Hakonarson,
ugusto D. Pichard, Kenneth M. Kent, Lowell Satler, Joseph M. Lindsay, Ron Waksman,
hristopher W. Knouff, Dawn M. Waterworth, Max C. Walker, Vincent E. Mooser, Jaume Marrugat,
avin Lucas, Isaac Subirana, Joan Sala, Rafael Ramos, Nicola Martinelli, Oliviero Olivieri,
lisabetta Trabetti, Giovanni Malerba, Pier Franco Pignatti, Candace Guiducci, Daniel Mirel,
elissa Parkin, Joel N. Hirschhorn, Rosanna Asselta, Stefano Duga, Kiran Musunuru, Mark J. Daly,
haun Purcell, Sandra Eifert, Peter S. Braund, Benjamin J. Wright, Anthony J. Balmforth, Stephen G. Ball,
yocardial Infarction Genetics Consortium, Wellcome Trust Case Control Consortium, Cardiogenics,
illem H. Ouwehand, Panos Deloukas, Michael Scholz, Francois Cambien, Andreas Huge, Thomas Scheffold,
eikko Salomaa, Domenico Girelli, Christopher B. Granger, Leena Peltonen, Pascal P. McKeown,
avid Altshuler, Olle Melander, Joseph M. Devaney, Stephen E. Epstein, Daniel J. Rader, Roberto Elosua,
ames C. Engert, Sonia S. Anand, Alistair S. Hall, Andreas Ziegler, Christopher J. O’Donnell,
ohn A. Spertus, David Siscovick, Stephen M. Schwartz, Diane Becker, Unnur Thorsteinsdottir,
ari Stefansson, Heribert Schunkert, Nilesh J. Samani, Thomas Quertermous
ecent prospective studies suggest that carriers of the 719Arg allele in kinesin-like protein-6
KIF6) are at increased risk of clinical coronary artery disease (CAD) compared with
oncarriers. Assimes and colleagues sought to confirm this association and genotyped subjects
n 19 case-control studies involving over 17,000 cases of CAD and 39,000 controls. None of
he 19 studies demonstrated an increased risk of CAD in carriers of the 719Arg allele.
egression analyses and fixed effect meta-analyses ruled out with a high degree of confidence
n increase of 2% in the risk of CAD with this allele. The KIF6 Trp719Arg polymorphism
as not associated with the risk of clinical CAD in this large replication study.
ditorial Comment: Eric J. Topol, Samir B. Damani, p. 1564(continued on page A-30)
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RARDIAC RESYNCHRONIZATION1567Effect of Biventricular Pacing on Diastolic Dyssynchronyiriam Shanks, Matteo Bertini, Victoria Delgado, Arnold C. T. Ng, Gaetano Nucifora,
utger J. van Bommel, C. Jan Willem Borleffs, Eduard R. Holman, Nico R. L. van de Veire,
artin J. Schalij, Jeroen J. Bax
hanks and colleagues examined the effect of cardiac resynchronization therapy (CRT) on
iastolic dyssynchrony in almost 300 subjects who underwent CRT placement. CRT
esponders were defined as having 15% decrease in left ventricular end-systolic volume at
months. At baseline, systolic dyssynchrony was present in 46%, diastolic dyssynchrony in
2%, and both in 29% of subjects. Compared to nonresponders, responders had longer
ystolic and diastolic delays at baseline. After 6 months, the systolic and diastolic delays
mproved in CRT responders but did not change in nonresponders. Further studies on the
athophysiology of diastolic dyssynchrony and its changes with CRT appear warranted.EART RHYTHM DISORDERS1576Post-Exercise ST-Segment Elevation Identifies High-Risk Brugada Patients1 second
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V5isaki Makimoto, Eiichiro Nakagawa, Hiroshi Takaki, Yuko Yamada, Hideo Okamura, Takashi Noda,
azuhiro Satomi, Kazuhiro Suyama, Naohiko Aihara, Takashi Kurita, Shiro Kamakura, Wataru Shimizu
akimoto and colleagues studied the prevalence and the clinical significance of ST-segment
levation during recovery from exercise testing in patients with Brugada syndrome (BrS).
ugmentation of ST-segment elevation 0.05 mV in V1 to V3 leads compared with baseline
as observed at 1 to 4 min into recovery in 37% of BrS patients and no control subjects.
uring follow-up, ventricular fibrillation occurred in 44% of the BrS patients with
T-segment elevation compared with only 17% in those without ST augmentation.
ugmentation of ST-segment elevation during recovery from exercise testing identifies BrS
atients with poor prognosis; it is thought to reflect either increased parasympathetic activity
uring this period or an abnormal cardiac response to this increased activity.ditorial Comment: Sami Viskin, Raphael Rosso, p. 1585EART RHYTHM DISORDERS1589Success of Catheter Ablation of IART in Adults With CHDing-Chien Yap, Louise Harris, Candice K. Silversides, Eugene Downar, Vijay S. Chauhan
ap and colleagues investigated the acute and long-term outcome of radiofrequency catheter
blation (RFCA) for intra-atrial re-entrant tachycardia (IART) in adults with congenital
eart disease (CHD). A total of 193 procedures were performed in 130 patients; 69% were
nitially successful. The use of electroanatomic mapping improved the likelihood of success,
hereas previous Fontan palliation or Mustard repair made success less likely. IART
ecurrence was noted in 48% of patients over a median of 4 years. In this population of adults
ith CHD, a previous history of complex atrial surgery reduces the likelihood of success of
FCA for IART.
